Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
DEJ Dejour Expands Woodrush Project*Company to Spud Two Wells in December 2014
DEJ Dejour Expands Woodrush Project*Company to Spud Two Wells in December 2014
Wow oh my that is really scary but hopefully your dream is just a warning to take it easy. Yes, definitely have that check up ...let the doctors have you checked inside and out. I am sure I would.
Good luck and keep us posted.
MSTX I hear you and I also take these targets with a grain of salt. They recently did an offering at 0.48 and now have nearly $70 million to fund further studies.
But regardless of what analysts say how can you not buy a 0.48 stock with a ph3 and few other promising in the pipeline.
They have no debt and a first known catalyst is expected before year end. Submitting protocol for a ph 2 on heart failure. MST-188 for sickle cell is in ph 3 and are on schedule.
Also several instuts have bought millions of shares including the Baker Brothers.
2015 is imo the year MSTX will start to break out perhaps even bigger than anyones guess. From here this is at least worth dipping your toe in. Buy, swing, add along the way and be patient. I see this getting approval in 2016.
Upcoming News and Events
•
Phase 2 Study (heart failure): submit protocol to FDA
Q4 2014
•
Nonclinical Study (heart failure): data (disclosed y'day 3 months in advance see pr)
Q1 2015
•
Nonclinical Study (embolic stroke): data
Q2 2015
•
Phase 2 Study (heart failure): initiate enrollment
1H 2015
•
EPIC Extension Study (repeat exposure): initiate enrollment
1H 2015
•
Phase 2a Study of AIR001 (WHO Group 2 PH): preliminary data
2H 2015
•
Phase 2 Study (heart failure): interim safety analysis
2H 2015
•
EPIC Study: complete enrollment
Q4 2015
•
EPIC Study: top-line data
Q1 2016
•
Phase 2 Study (acute limb ischemia): complete enrollment
2H 2016
MSTX new $3 target
Highline Research Advisors, LLC, a Merriman Capital, Inc. Financial Entrepreneur Platform participant announced today that research analyst Michael Higgins has initiated equity research coverage of Mast Therapeutics (AMEX: MSTX) with a Buy rating and a $3.00 price target
Gold recovers losses to trade near USD 1200
Wed, Nov 19 2014, 08:25 GMT
US shale and OPEC oil: Game of chicken?
By Matt Clinch
1 hour ago
The political rhetoric surrounding the recent drop in oil prices shows no signs of slowing, with Venezuela said that oil producing countries could soon meet to discuss the tumbling commodity.
In a televised address late Monday, Venezuela President Nicolas Maduro said that a gathering of both Organization of the Petroleum Exporting Countries (OPEC) countries and non-OPEC countries was being planned, according to the Associated Press.
The discussions would be in the lead-up to a crucial OPEC meeting which is taking place in Vienna on November 27, and although Maduro was slim on details, he said he was confident that fellow OPEC nations would join together to help prices recover.
It comes as Venezuela Foreign Minister Rafael Ramirez is currently on a tour of oil-producing nations including Russia and the Gulf States.
New chapter
Global oil prices have plunged since peaking in June. From around $115 a barrel, Brent crude (: @LCO13Z-GB) has lost around a third of its price and was trading near four-year lows on Tuesday at $79. Weak demand, a strong dollar and booming U.S. oil production are the three main reasons behind the fall, according to the International Energy Agency (IEA), which warned of a "new chapter" for oil markets, which could even affect the social stability of some countries.
Read More Cracks widen at OPEC as oil prices tumble
This shift was further underlined on Tuesday, when Reuters reported that Iraq was looking to base its 2015 budget on an oil price of $80 per barrel.
The OPEC nations - which include the main swing producer, Saudi Arabia - are seen as key to the market, as they could agree to cut production and provide a floor for the price. However, political ramblings and a lack of formal production quotas have led many analysts to say that OPEC is unlikely to announce new policy at the end of the month.
"(The fall in price) is not helping any of the members of the cartel right now," Abhishek Deshpande, oil and gas analyst at French investment bank Natixis, told CNBC on Tuesday, but added that any sort of agreement between OPEC and non-OPEC nations could be a lame duck.
He added that a previous agreement between the two sides had been limited in scope, with only Norway curbing oil production - and it wouldn't be any different this time around. A price of $50 a barrel for Brent crude couldn't be ruled out if next week's meeting disappointed the markets, Deshpande said.
'Game of chicken'
BNP Paribas oil analysts, led by Harry Tchilinguirian, agreed that prices were more likely to move lower than higher after next week's meeting, and warned of serious volatility, with the U.S. market closed for the Thanksgiving holiday.
Andre Loes, chief Latin America economist at HSBC, was also relatively pessimistic, telling CNBC on Tuesday that he expected only a slight increase in the price over the next few months.
One possible consequence of a lower oil price is a fall in U.S. shale oil production. Earlier this month, the IEA said falling prices could cut investment in U.S. shale oil by 10 percent next year, slowing growth in a sector that has turned America into a major global producer.
Read More Brent slips to $79 as Japan enters recession
But Tchilinguirian highlighted that some analysts believed the OPEC nations would let the oil price decline further to "crowd out" the U.S., as shale production costs are higher than traditional oil production.
"This assumes OPEC has forfeited its role and has lost control of the price," he said in a research note on Monday. "We stand on the other side of the argument, namely that to try to crowd out U.S. oil supply in 2015 is futile as lower price levels would be required for a prolonged period of time."
As a result, the cost would be too great for the cartel, he said, adding that Saudi Arabia - one of OPEC's most flexible oil producer - was playing a "game of chicken", to incentivize collective action between the nations.
Iran nuclear deal
Iran could throw yet more uncertainty into the mix this week, with negotiations on its nuclear program meaning that economic sanctions from the U.S. could be eased - paving the way for even more oil production from the Middle East.
Read More Saudi minister: It's all a 'misunderstanding,' no 'price war' talk
Analysts at Citi investment bank said that a production cut from OPEC was marginally more likely than a nuclear deal for Iran, but added that they were not expecting either to happen in the next two weeks.
"How credible the market finds any announcement of a cut remains to be seen," the analysts, led by Seth Kleinman, said in a note late Monday. "The length of time that has passed since (the) last big cut during the (global financial crisis) is but one measure of how little the group has had to do in recent years and how out of practice the negotiators are."
Gold rises above $1200
FXStreet (Mumbai) - Gold prices rose above USD 1200 for the first time since Oct. 31st, tracking the weakness in the US Dollar and currencies of the other advanced economies.
Gold traded 1.48% higher at USD 1201.00/Oz levels at the time of writing. Moreover, Gold prices have recovered due to the weakness in the US Dollar and other major currencies. Moreover, the yellow metal gained as one major central bank after another turned dovish in the first half of the current month. The aggressive stimulus from the Bank of Japan, followed by the dovish Bank of England’s quarterly inflation report along with the European Central Bank’s readiness to purchase sovereign bonds has weakened their respective currencies, thereby providing support to the Gold prices.
Meanwhile, the US Dollar also weakened, trading down 0.35% at 87.70 levels. The yellow metal may advance further as the US Treasury yields are showing signs of weakness.
Gold Technical Levels
Gold has an immediate support at 1193.60, under which the looses could be extended to 1180.80 levels. On the other hand, Gold may rise to 1215, if the immediate resistance at 1206 is breached.
Lol I think the server has a hickup
I agree.
I agree.
I agree.
I strongly doubt it goes that low.
Members of Opec are due to meet later this month on the 27th to discuss the global oil price.
I strongly doubt it goes that low.
Members of Opec are due to meet later this month on the 27th to discuss the global oil price.
BRIEF-MDxHealth raises 12.33 mln euros in equity offering
MDxHealth SA
MDXH.BR
€3.60
----
11/04/2014
Nov 5 (Reuters) - MDxHealth SA :
* Raises 12.33 million euros ($15.43 million) in equity offering
* Private placement of 3,425,000 new shares at 3.60 euros (or $4.51) per share
* Closing price of MDxHealth shares on Euronext Brussels on Nov. 4, before launch of private placement was 3.599 euros per share
* Petercam NV/SA acted as sole lead manager and book runner in the private placement Source text for Eikon: Further company coverage: (Gdynia Newsroom: +48 58 698 39 20; Gdynia.newsroom@thomsonreuters.com)
BAA not sure that this will do it with gold price dropping. But should be good enough for a trade.
BAA Sign Definitive Agreement for US$41 Million Gold Sale Transaction
Banro Corporation
4 minutes ago
????
TORONTO, ONTARIO--(Marketwired - Nov 4, 2014) - Banro Corporation ("Banro") (NYSE MKT:BAA)(BAA.TO) is pleased to announce, further to Banro's October 15, 2014 and August 18, 2014 press releases, the signing of the definitive agreement with Gold Holding Ltd. ("Gold Holding") for the US$41 million gold sale transaction relating to the Twangiza mine. This transaction, which is expected to close within the next few weeks, involves the prepayment by Gold Holding of US$41 million for its purchase of 40,500 ounces of gold (amended from 40,000 ounces of gold) from the Twangiza mine, with the gold deliverable over four years, at 10,125 ounces per year. The contemplated US$80 million gold sale transaction with Gold Holding relating to the Namoya mine, as referred to in Banro's October 15, 2014 and August 18, 2014 press releases, is anticipated to close before the end of this calendar year subject to finalizing the definitive agreement with Gold Holding. Reference is made to the said press releases for additional information with respect to both the Twangiza and Namoya transactions.
MDXH.BR Q3 results are very good
IRVINE, CA, and HERSTAL, BELGIUM, November 4, 2014 - MDxHealth SA (Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today provided its third quarter Business Update for the period ended September 30, 2014.
"The posting of our final Local Coverage Determination (LCD) for Medicare and confirmation of a $2,030 reimbursement price for Medicare patients is further validation of the clinical value of ConfirmMDx for Prostate Cancer and will have a material impact on market adoption and product revenues," stated Dr. Jan Groen, CEO of MDxHealth. "In Q3 2014, ConfirmMDx revenue grew 93% to $3.1 million, versus the $1.6 million recorded in Q3 2013, and increased 175% in the first nine months of 2014 to $7 million, as compared to $2.5 million in the same period last year. These gains are driven by continuing adoption of the ConfirmMDx test by the U.S. urology community, with over 3,500 patient tests in Q3 2014, and more than 9,000 tests performed year to date."
Dr. Groen continued: "We are also excited about the FDA approval and Medicare coverage of our licensee Exact Sciences' Cologuard® test for colon cancer screening and we expect to begin to recognize additional milestone revenue and product royalties in the quarters ahead."
Q3 2014 Highlights
?Overall revenues increased 78% to $3.5 million in Q3 2014 versus $2.0 million in Q3 2013
?ConfirmMDx revenue nearly doubled to $3.1 million in Q3 2014 from $1.6 million in Q3 2013
?For the first 9 months of 2014, overall revenues increased significantly to $8.3 million, compared to $6.0 million in the same period last year
?ConfirmMDx case volume rose 64% to over 3,500 tests in Q3 2014, compared to 2,100 tests in Q3 2013
?In the first 9 months of 2014, case volume doubled to more than 9,000 patients tested, versus 4,500 tests in the same period last year
?Since ConfirmMDx was launched in May 2012, over 17,000 tests have been ordered by nearly 1,800 urologists
?The final Medicare LCD for coverage of ConfirmMDx became effective November 3, 2014
?A co-marketing agreement for ConfirmMDx was signed with Miraca Life Sciences (MLS)
?Insurance agreements signed with Ancillary Care Services (ACS) and Consilium, LLC
?The results from an important study, published in The Journal of Urology® suggests that ConfirmMDx biomarker is associated with the risk of recurrence for early stage prostate cancer patients
Other Business Activities
?MDxHealth's licensee Exact Sciences launched its FDA-approval Cologuard test, making it the first and only approved stool-based DNA test for the detection of colorectal cancer
?Exact Sciences received its final National Coverage Determination (NCD) for Cologuard from the Centers for Medicare & Medicaid Services (CMS). Based on cross walk analysis, the expected Cologuard reimbursement price is $502 for Medicare patients
Events after the Reporting Period
?Publication of the DOCUMENT clinical validation study in the October issue of The Journal of Urology® confirmed the performance of the ConfirmMDx test in a U.S. multicenter cohort
?ConfirmMDx® genes were shown to correlate with prostate cancer (PCa) aggressiveness in diagnostic biopsies. The data were presented at the European Association of Urology (October 9-11, 2014)
Key non-audited financials as of September 30, 2014
Amounts at and for the three months ended:
Dollars thousands Sept 30, 2014 Sept 30, 2013
Total Revenues 3,496 1,995
EBITDA (Loss) (3,465) (3,895)
EBIT Operating Income (Loss) (3,552) (3,953)
Net Profit (Loss) (4,193) (3,945)
Cash and cash equivalents 7,611 28,433
Amounts at and for the nine months ended:
Dollars thousands Sept. 30, 2014 Sept 30, 2013
Total Revenues 8,299 5,979
EBITDA Income (Loss) (11,398) (11,420)
EBIT Operating Income (Loss) (11,637) (11,772)
Net Profit (Loss) (12,237) (11,787)
Cash and cash equivalents 7,611 28,433
Commercial revenues up 39% for the first 9 months
Total Revenues for the first nine months amounted to $8.3 million, a 39% growth over the previous year, primarily due to an increase in ConfirmMDx test sales, which grew by 175% during the same period.
Operating Expenses were $15.7 million in the first nine months of 2014, versus $14.1 million in the same period in 2013, as the company continued to invest in the development of its product pipeline, and sales, marketing, managed care, and clinical study activities in the U.S.
The Net Loss of $12.2 million for the first nine months of 2014 increased by $0.45 million compared to the same period last year. Continued investment in the US commercial operation and higher cost of sales due to the increasing test volumes for the ConfirmMDx for Prostate Cancer test were offset by higher recognized revenue from its sale.
Cash Position as of September 30, 2014 was $7.6 million in cash and equivalents, compared to $28 million on September 30, 2013. Average net cash burn in the first nine months of 2014 was slightly less than $1.9 million per month.
Outlook
We anticipate continued strong growth in ConfirmMDx for Prostate Cancer test volumes and revenue for the rest of 2014 and into 2015 with our current sales force, enabling us to allocate more resources toward reimbursement, billing and collections efforts. Additionally the Centers for Medicare and Medicaid Services (CMS) publication of the final Local Coverage Determination (LCD) for ConfirmMDx for Prostate Cancer, with a Medicare reimbursement rate of $2,030 and an effective date of November 3rd, is also important for the company's managed care strategy with private insurance companies. The LCD validates that ConfirmMDx is deemed reasonable and necessary by Medicare, bolstering the value of the test in the marketplace.
With increasing ConfirmMDx test volumes and the expansion of our reimbursement and collection department, MDxHealth is able to collect more cash and recognize more accrual-based revenue. However, with growing adoption of the test by new prescribing urologists across the U.S., the company expects a growing number of new payors, thus also increasing the group of non-contracted, third party payors. This could lead to continued delays in collections and revenue recognition among those payors specifically. At the end of Q3 2014, the company engaged with over 430 payors from which reimbursements have been obtained from over 280 payors, as compared to 155 payors reported in the first half of this year.
MDxHealth has started enrollment for the prospective clinical utility study, PASCUAL, which will generate additional clinical utility data supporting continued Medicare coverage of the ConfirmMDx for Prostate Cancer test. At the date of the release of our Q3 results over 50% of the number of patients required to complete the interim analysis have been enrolled. The completion of interim analysis of the PASCUAL study, as outlined in the Medicare LCD, is expected in the first half of 2015, potentially triggering expanded Medicare coverage.
With the launch of licensee Exact Sciences' FDA-approval Cologuard test, MDxHealth expects to recognize a milestone fee and deferred license fees in excess of $0.5 million in the near term. In addition, pursuant to its license agreement with Exact Sciences, MDxHealth is eligible to receive minimum annual maintenance fees of $100,000 per year, sales milestones of $300,000 after Cologuard attains net sales of $10 million, $750,000 after Cologuard attains net sales of $50 million, and $1 million after Cologuard attains net sales of $50 million in a single calendar year, as well as running royalties in the mid-single digit range. The license agreement is expected to remain in effect until the last of the licensed patents expires in 2028.
About MDxHealth
MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. By applying patented DNA methylation platform and biomarkers, MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. For more information visit http://www.mdxhealth.com.
For more information:
Dr. Jan Groen, CEO Mike Sinclair (media)
MDxHealth Halsin Partners
US: +1 949 812 6979 +44 20 7318 2955
BE: +32 4 364 20 70 Cell: +44 7968 022075
info@mdxhealth.com msinclair@halsin.com
MSTX The third quarter was productive for Mast. Consistent with prior guidance, our 388-patient pivotal Phase 3 study of MST-188 for sickle cell disease is on track to complete enrollment by the end of next year. We now have opened 50 study sites in the U.S. and more than ten study sites in six countries outside of the U.S."
Upcoming News and Events
•
Phase 2 Study (heart failure): submit protocol to FDA
Q4 2014
•
Nonclinical Study (heart failure): data
Q1 2015
•
Nonclinical Study (embolic stroke): data
Q2 2015
•
Phase 2 Study (heart failure): initiate enrollment
1H 2015
•
EPIC Extension Study (repeat exposure): initiate enrollment
1H 2015
•
Phase 2a Study of AIR001 (WHO Group 2 PH): preliminary data
2H 2015
•
Phase 2 Study (heart failure): interim safety analysis
2H 2015
•
EPIC Study: complete enrollment
Q4 2015
•
EPIC Study: top-line data
Q1 2016
•
Phase 2 Study (acute limb ischemia): complete enrollment
Balance Sheet Highlights
As of September 30, 2014, the Company had cash, cash equivalents and investment securities totaling $43.1 million. Stockholders' equity amounted to $45.2 million as of September 30, 2014.
EXAS today announced that Meriter-UnityPoint Health will now offer Cologuard®, the first and only FDA approved noninvasive stool DNA screening test for colorectal cancer.
Cologuard analyzes a person's stool to detect both altered DNA and blood known to be associated with colorectal cancer and precancer. Cologuard has been proven to find 92 percent of colorectal cancers in average risk patients with 87 percent specificity. Unlike many other screening options, Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test.
...But for those who are not willing to have a colonoscopy, this is a non-invasive option to provide them. We're here to prevent illness and save lives."
Colorectal cancer is the second-leading cancer-related cause of death in the United States. It is often considered the most avoidable, yet least prevented cancer due to the lack of patient compliance with current screening options. Most colorectal cancers develop slowly over several years. Unfortunately, 23 million Americans aged 50 and over do not get screened as recommended.
They already received 1000 orders between FDA approval October 6th and since CMS decision 1150.
That would be $1 million in orders already.
I am betting on the Belgian company MdxHealth who licenced the two most important biomarkers to EXACT. The more Cologuard sells the more royalties income rolls over to MDXH.BR. And who also have their own prostate test on the market in the US and in Israel (agreement with TEVA).
HTM very nice update
Our units are all performing with exceptionally high availabilities, and with output that is at or above what we had expected. The total generation from all of our units for the first nine-months of 2014 was 242,276 megawatt-hours, compared to 213,184 megawatt-hours for the first nine-months of 2013, reflecting a 14% increase over the prior year period," said Dennis Gilles, Chief Executive Officer of U.S. Geothermal. "As a result of this strong performance, we anticipate our projected year-end results should be at the higher end of the guidance range previously provided."
"We are very pleased with our accomplishments to date, and are optimistic with the growth opportunities that lie ahead for our company and its shareholders," said Dennis Gilles, Chief Executive Officer of U.S. Geothermal Inc. "We are currently well capitalized, and with the addition of our positive cash flows from operations, are well positioned to fund internal development, and growth through strategic M&A activities, as was demonstrated with our most recent Geysers acquisition which we acquired with cash off our balance sheet."
The Company expects to release third quarter financial results, along with 2014 and 2015 guidance, on November 13, 2014 with the earnings call on November 14, 2014 at 11:00 am Eastern.
DEJ suprised there isn't more interest in this company if you look at their assets and future projects.
It should be trading at $1 minimum instead.
Hanging on to my shares till I see this number on my screen :)
Cheers!
DEJ US Oil Boom - This Colorado Shale is The Next Big Thing
LONDON, October 22, 2014 /PRNewswire/ --
One of North America's older, more mature plays, the Rocky Mountain's Piceance Basin doesn't get the same media attention as the newcomers, but there is a flurry of game-changing drilling that will render this liquids-rich haven a major rival.
What has really got everyone's attention is the potential for high-value oil liquids coming from the Niobrara and Mancos shales located in the Piceance Basin.
There is an estimated 300 trillion cubic feet of natural gas resource in Colorado's Piceance Basin, with producers thus far reporting an estimated 20% liquids recovery.
In the eastern portion of the Basin, there is one player nicely positioned for big gains and that is Dejour Energy Inc. (NYSE MKT: DEJ / TSX: DEJ). Dejour feels that it has found a winner with its Kokopelli Field.
Kokopelli is the current highlight of Dejour's portfolio, with its 25% working interest in 2,200 acres in this gas- and liquids-prone property, where production is returning 25% NGLs on a BOE basis. Kokopelli currently has 11.5 million barrels of proved and probable oil reserves along with 250 BCF natural gas worth $260mm. And that's before we factor the game-changing potential available this December from the Mancos/Niobrara drill logs.
There is evidence for Dejour's optimism. Two major producers - Bill Barrett Corporation and WPX Energy directly border Dejour's holdings, further raising the prospects for that acreage. Barrett's assets were just purchased by the giant Vanguard Natural Resources LLC for over $1 billion. WPX Energy is the largest Williams Fork developer and most successful Mancos explorer to date. Kokopelli is sandwiched right between these two success stories.
Dejour already has four Williams Fork wells producing liquids-rich natural gas at Kokopelli with an impressive 50 barrels / mmcf gas since 2013. The current $16 million drilling program promises another eight wells by the end of this year with the rig already on site and first well spud on October 9, 2014. Updates will be forthcoming over the next several months.
The company's financials are also impressive. Dejour's revenues are up 35%, debt is minimal, cash-flow has been positive for six months and acquisitions/drilling at its legacy Woodrush Project in Canada are expected to deliver a further upswing.
On balance, Dejour appears poised for explosive growth with multiple research analyst eyes now beginning to view the Company.
MSTX new CEO blog http://www.masttherapeutics.com/company/ceo-blog/
MDxHealth's ConfirmMDx Genes Identify Prostate Cancer Aggressiveness in Diagnostic Biopsies
IRVINE, Calif. and HERSTAL, Belgium, Oct. 10, 2014 (GLOBE NEWSWIRE) -- MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced positive data from an important study confirming the ability of the ConfirmMDx® genes to identify prostate cancer (PCa) aggressiveness in diagnostic biopsies. The data, presented at the European Association of Urology, Section Urological Research (ESUR) meeting in Glasgow, UK (October 9-11, 2014), confirmed that the epigenetic profile of ConfirmMDx genes generated by the test is strongly correlated with established risk stratification metrics, such as Gleason Score (GS) and the NCCN (National Comprehensive Cancer Network) risk categories.
www.virtual-strategy.com/2014/10/10/m...
If EXAS can jump 35% on medicare coverage so should MDXH...at some point ;)
Jefferies: $EXAS Seatbelts On: Preliminary CMS Pricing = Bull Case Scenario; Hiking Target to $27 (from $20)
$EXAS JMP "Above all Expectations" - price target to $34 from $28 following CMS' decision on Cologuard's coverage and reimbursement
Now is the time to buy MDXH!
MDXHealth Share To Double, Triple Or More In 2015?
http://www.snj-biostoxx.eu/mdx-health.html
MDXH MDXHealth price target EUR 7.80:
"We start following MDXHealth with an initial share price target of EUR 7,80, reflecting a share price increase of 96% compared to the 3 October price of EUR 3,96.
- MDXHealth is undervalued at 4 Euro or a 140 million Euro.
- Its price is not consistent with conservative Cologuard royalty prospects (rate 3%) if the market adequately prices Exact Sciences (the company that developed and commercializes Cologuard). We attach a net present value of these future royalties that exceeds the full share price of MDXHealth (i.e. EUR 4,57 per share)
- Beyond the main scenario, the company has the potential for exponential growth in value of sales in its main product ConfirmMDX pick up and if new markets are commercialized.
-In case SNJ-Biostoxx "accelerating sales" or "sunshine scenario" would tend to materialize, we expect a take-over of the company by 2015 with take-over price at least in the range 10-15 Euros.
- Main short-term risks relate to the negative cash flow and probable need for a capital increase or credit line, as expenses are increasing with sales but timing of cash flows are uncertain (milestone payments, royalties, medicare repayments, etc). A small capital increase or a strategic stake by a large biotech or pharma company could reduce uncertainty on these issues.
- Short-run triggers for upward stock movement include: (i) news on Cologuard sales and forward guidance by Exact Sciences: if sales exceed 50.000 patients already in 2014, MDX may get milestone payments up to $ 2 million this year; it will also raise expectations about future royalty streams; (ii) increasing sales of ConfirmMDX reported on 4 November 2014; (iii) collection of outstanding reimbursements of performed test including by Medicare; (iv) announcement of new partnerships or launch of products outside the US.
www.snj-biostoxx.eu/mdx-health.html
MSTX up in PM announces Appointment Of Chief Medical Officer
PR Newswire
SAN DIEGO, Oct. 2, 2014 /PRNewswire/ -- Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company, announced today that Edwin L. Parsley, D.O. has joined the Company as its Chief Medical Officer and Senior Vice President.
Dr. Parsley has been actively engaged with the Company since it acquired Aires Pharmaceuticals, Inc. in February 2014. He has served as Mast's interim Chief Medical Officer since September 2014 and as Chief Medical Officer of Aires since April 2011. Dr. Parsley previously was with Pfizer, where he oversaw clinical trials for Revatio® (sildenafil). He is a practicing physician and certified by the American Board of Internal Medicine in internal medicine, pulmonary disease, critical care medicine, and sleep medicine.
"Ed brings significant drug development and clinical expertise, as well as over 25 years of experience treating patients with a range of acute care needs, including patients with sickle cell disease, heart failure and stroke in emergency department and inpatient settings," stated Brian M. Culley, the Company's Chief Executive Officer. "Over the seven months since we acquired Aires, Ed has made valuable contributions to our programs and we are delighted he has joined our team. We believe his experience will help us achieve our clinical and preclinical development goals over the next 12 to 18 months," Mr. Culley continued.
"I am very pleased to join Mast at this exciting time in the Company's history," said Dr. Parsley. "With its ongoing Phase 3 study of MST-188, Mast is a leader in a rare disease for which there is significant unmet need and I look forward to helping the Company achieve its goal of bringing to market the first FDA-approved drug for sickle cell disease in over 16 years, as well as advancing the Company's development programs in heart failure and arterial disease."
MSTX way too low with what they have in their pipeline. Nearly $50 million in cash.
http://seekingalpha.com/article/2534005-why-imminent-orphan-status-designation-will-attract-big-pharma-to-mast-therapeutics
SA Article Highlites/Summary
"Summary
•Likely positive orphan status opinion for MST-188 (for ALI) in EU next week provides imminent catalyst.
•Big pharma are actively acquiring and partnering with small biotechs treating sickle cell disease like MSTX.
•This week's setback by sickle cell disease competitor (GLYC) creates advantage for MSTX.
•Recent analyst opinion points to upside of 100%+ based on MSTX price target of $1.20.
Why Imminent Orphan Status Designation Will Make Mast Therapeutics Attractive to Big Pharma
It is official. Within days, Mast Therapeutics (NYSEMKT:MSTX) is likely to receive a positive opinion granting orphan medicinal product status to their lead product candidate MST-188 for treatment of acute limb ischemia (ALI) at the EU's Committee for Orphan Medicinal Products meeting to begin on October 7."
Wow nice! Taking profits always good. Markets are not what they used to be unfortunately.
MDXH MDxHealth's ConfirmMDx for Prostate Cancer Test Qualifies for Medicare Coverage Effective November 3, 2014 -
IRVINE, California, and HERSTAL, BELGIUM - September 23, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that its ConfirmMDx® for Prostate Cancer test qualifies for Medicare coverage effective November 3, 2014.
The Centers for Medicare and Medicaid Services (CMS) released the final version of the coverage policy issued by Palmetto GBA, the Medicare administrator responsible for the MolDx technology assessment program that evaluated the ConfirmMDx test:
MolDX Title: ConfirmMDx Epigenetic Molecular Assay
LCD#: L35368
As part of an ongoing commitment to ensure that Medicare covers the appropriate use of the ConfirmMDx test, Palmetto GBA expects MDxHealth to continue accruing patients in the prospective, randomized PASCUAL clinical utility trial currently in process, and to enroll providers into it's Certification and Training Registry. The LCD provides for coverage initially limited to patients of physicians enrolled in the ConfirmMDx Registry. MDxHealth will conduct an interim analysis of the PASCUAL study to determine the repeat biopsy rate, and expects to complete the interim analysis in 2015. Provided the interim analysis yields positive results showing a substantially lower repeat biopsy rate, Palmetto will expand physician participation in the ConfirmMDx Registry, effectively increasing the number of Medicare patients covered. If the interim analysis demonstrates poor accrual, or fails to demonstrate a substantially decreased repeat biopsy rate, the LCD indicates that limited coverage will continue until either 1,200 patients have been tested or 3 years from the effective date of the LCD, which ever occurs first. MDxHealth expects to have tested 1,200 patients within the PASCUAL trial and the Registry by Q2 2016. Unrestricted Medicare coverage, with the Registry requirement removed, is expected with favorable PASCUAL trial findings.
"The ConfirmMDx for Prostate Cancer test is an important tool validated to aid urologists with management of patients suspected to harbor undetected prostate cancer and the need for a repeat biopsy. The PASCUAL clinical trial is an opportunity to prospectively demonstrate how urologists utilize the test results in a patient population with a previous negative biopsy result," said principal study investigator Neal Shore, M.D. Medical Director, Carolina Urologic Research Center Partner, Atlantic Urology Clinics, Myrtle Beach, South Carolina. "Prostate cancer is one of the most common cancers in U.S., with 1 in 6 men diagnosed during their lifetime. Prostate cancer can be most effectively treated if caught early, so ConfirmMDx serves a vital role. The ConfirmMDx test provides valuable genomic insights beyond standard pathology review, helping urologists make informed decisions about the need for repeat biopsy on high risk patients."
"We are pleased to announce this important milestone for the ConfirmMDx test, and MDxHealth. The decision by Palmetto GBA's MolDX technology assessment program to cover ConfirmMDx for Medicare beneficiaries under the conditions set forth in the LCD establishes ConfirmMDx as a "reasonable and necessary" test for the management of men suspected to have occult cancer. Medicare's decision will facilitate negotiations with private insurance companies as well," stated Dr. Jan Groen, CEO of MDxHealth. "Initial patient enrollment in the PASCUAL trial has been robust and we are confident this study will yield positive results corresponding to those already reported in the clinical utility study we published earlier this year
MSTX PT $1,20 Raised at Piper Jaffray Following Sickle Cell Conference; Sees 100% Upside
Piper Jaffray analyst Edward Tenthoff lifted his price target on Overweight-rated Mast Therapeutics (NYSE: MSTX) to $1.20 (from $1.00) following yesterday's Piper Jaffray sponsored the 3rd Annual Sickle Cell Disease Therapeutics Conference.
"Prominently featured was Mast Therapeutics' MST-188, which is currently enrolling the 388-patient Phase III EPIC trial to shorten vaso-occlusive crisis (VOC)," Tenthoff notes.
He also highlighted:
Phase III EPIC Trial Enrollment On Track
Phase II ALI Study Underway.
MST-188 Heart Failure Potential.
Encouraging Phase II AIR001 PAH Data
For an analyst ratings summary and ratings history on Mast Therapeutics click here. For more ratings news on Mast Therapeutics click here.
Shares of Mast Therapeutics closed at $0.59 yesterday.
MDXH MDxHealth Rodman & Renshaw 16th Annual Global Investment Conference
IRVINE, California, and HERSTAL, BELGIUM - September 8, 2014 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will participate in the Rodman & Renshaw 16th Annual Global Investment Conference in New York, NY.
Dr. Jan Groen, Chief Executive Officer of MDxHealth, will present a corporate overview at the Rodman & Renshaw 16th Annual Global Investment Conference at the New York Palace Hotel at 4:10 p.m. ET on Tuesday, September 9, 2014
HTM Tesla aims to utilise geothermal for its new battery plant in Nevada
Tesla Motor’s CEO, Elon Musk explains that geothermal and other renewable energy will fuel the new projected Gigafactory to be built in Nevada.
Following last week’s decision from Tesla to definitely start its new plant in Reno, Nevada as reported by ThinkGeoEnergy, the company´s CEO has stated that said plant will be powered by renewable energy, being geothermal a key part of the green energy mix.
The decision of to start the manufacturing plant for the battery plant in Nevada is primarily motivated by the geographical location and its proximity to the current manufacturing plant in California, the incentives by the local administration and the availability of renewable energy in the area.
According to local news, “Musk also said Tesla will make every effort to make the plant look good and to have geothermal, wind and solar power provide the energy it needs to operate.”
The plant will be a generator of jobs and a great boost to the local economy, fuelled by geothermal and other renewable energies.
HTM buy rating $ 1.20 TP
Maxim Group Initiates Coverage on U.S. Geothermal (HTM): buy rating with target price of $1.20
MSTX watch for 0.75 break for an explosive move imo
Fantastic pipeline ph 2 and ph 3 and $50 million cash.
MSTX Mast Therapeutics Announces Positive Top Line Results From Phase 2 Study Of AIR001 For Pulmonary Arterial Hypertension And AIR001 Clinical Development Plan
- Data show improvements in hemodynamic parameters and exercise capacity
- AIR001 well-tolerated, with no treatment-related serious adverse events
- Data support further clinical development in pulmonary hypertension (PH)